FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy Journal Articles Refereed uri icon

Overview

Published in

  • Clinical and Experimental Pharmacology and Physiology

Time

Date/time value

  • 2012

Identity

Digital Object Identifier (DOI)

  • 10.1111/j.1440-1681.2012.05726.x

Additional Document Info

Parent Title

  • Clinical and Experimental Pharmacology and Physiology

Volume

  • 39

Issue

  • 8

Publisher

  • Blackwell Science Asia